In contrast, the MEK inhibitor-sensitive lung cancer cell lines are enriched with KRAS mutations (Fig. 5b), suggesting that DREBIC analysis is capturing the inherent biology of these cells as oncogenic KRAS mutant cells dependent on aberrant MEK signaling pathway. The gene discussed is KRAS; the disease is lung carcinoma.